FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月21日 | 2. 股份分類 | | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | | 說明 | | 人民幣股份 （於深圳證券交易所主板上市，股份代號：000513) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | | 2025年8月2 ...

Core Viewpoint - The innovative drug sector is experiencing a rebound, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a positive performance after a brief decline, indicating renewed investor interest in the sector [1][3]. Company Performance - LIZHU Pharmaceutical reported a mid-year revenue of approximately 6.272 billion yuan, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders increased by 9.4% to about 1.281 billion yuan [2]. - The company has 39 products in the research pipeline, with 13 in the registration phase, 4 in Phase III clinical trials, 2 in process validation/BE phase, and 4 in Phase II clinical trials [2]. Industry Trends - High-level leaders emphasized the need for increased high-quality technological supply and policy support for the biopharmaceutical industry, aiming to enhance the quality and efficiency of drug development [3]. - CICC expressed optimism about the long-term development trend of innovative drugs, highlighting the advantages of domestic engineers, abundant clinical resources, and supportive policies [3]. - The innovative drug sector is transitioning from a follower to a leader in innovation, with domestic products expected to significantly participate in the global market over the next decade [3]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain [3]. - The index has shown a remarkable year-to-date increase of 101.58%, outperforming the Hang Seng Index and the Hang Seng Tech Index by 78.08 and 79.53 percentage points, respectively [6][7].

Core Viewpoint - The innovative drug sector is experiencing a rebound, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a price increase of 1.36% on August 21, following two days of decline, indicating a positive market sentiment towards innovative pharmaceuticals [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) recorded a trading volume of 2.78 billion yuan, reflecting strong investor interest [1]. - Key stocks in the innovative drug sector, such as King’s Ray Biotechnology and Lepu Biopharma, saw price increases of over 6%, while others like Livzon Pharmaceutical and Crystal Technology rose by more than 5% [1][2]. Group 2: Company Performance - Livzon Pharmaceutical reported a revenue of approximately 6.272 billion yuan for the first half of the year, a slight decrease of 0.17% year-on-year, but net profit increased by 9.4% to about 1.281 billion yuan [2]. - The company has 39 products in the research pipeline, with 13 in the registration phase and 4 in Phase III clinical trials, indicating a robust development strategy [2]. Group 3: Policy and Industry Outlook - Recent government initiatives emphasize enhancing high-quality technological supply and policy support for the biopharmaceutical industry, aiming to boost innovation and production of effective new drugs [3]. - China International Capital Corporation (CICC) expresses optimism about the long-term development of the innovative drug industry, highlighting the advantages of domestic engineering talent, rich clinical resources, and supportive policies [3]. - The innovative drug sector is transitioning into a 2.0 era, with expectations for significant participation in the global market over the next decade, supported by improved cash flow and R&D cycles [3]. Group 4: Index Performance - The Hang Seng Stock Connect Innovative Drug Select Index has seen a cumulative increase of 101.58% year-to-date as of July 31, significantly outperforming other indices [6]. - The index has shown exceptional performance compared to the Hang Seng Index and the Hang Seng Technology Index, exceeding their returns by 78.08 and 79.53 percentage points, respectively [6].

Core Viewpoint - Lijun Pharmaceutical (01513) experienced a stock price increase of over 6%, with a current price of 38.7 HKD and a trading volume of 42.3845 million HKD, following the announcement of its 2025 first-half performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 6.272 billion RMB, representing a year-on-year decrease of 0.17% [1] - The net profit attributable to shareholders was around 1.281 billion RMB, showing a year-on-year increase of 9.4% [1] - Basic earnings per share were reported at 1.43 RMB [1] Research and Development - As of July 31, 2025, the company has 39 products in the research pipeline [1] - The products are at various stages: 13 in the listing application stage, 4 in Phase III clinical trials, 2 in process validation/bioequivalence stage, and 4 in Phase II clinical trials [1] - The company has achieved significant R&D results in the first half of the year, leveraging optimized R&D management and deep application of AI digital tools [1]

Core Viewpoint - Lijun Pharmaceutical (01513) reported a slight decrease in revenue for the first half of 2025, but showed a significant increase in net profit, indicating a positive trend in profitability despite revenue challenges [1] Financial Performance - Revenue for the first half of 2025 was approximately 6.272 billion yuan, a year-on-year decrease of 0.17% [1] - Net profit attributable to shareholders was around 1.281 billion yuan, reflecting a year-on-year increase of 9.4% [1] - Basic earnings per share stood at 1.43 yuan [1] Research and Development - As of July 31, 2025, the company had a total of 39 products in the research pipeline [1] - Among these, 13 products are in the registration phase, 4 in Phase III clinical trials, 2 in process validation/bioequivalence stage, and 4 in Phase II clinical trials [1] - The company has achieved significant R&D results in the first half of the year, leveraging optimized management and deep application of AI digital tools [1]

Core Viewpoint - Lijun Pharmaceutical (01513) reported a mixed performance for the first half of 2025, with a slight decline in revenue but an increase in net profit, reflecting effective R&D management and the application of AI digital tools [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 6.272 billion yuan, a year-on-year decrease of 0.17% [1] - The net profit attributable to shareholders was around 1.281 billion yuan, representing a year-on-year increase of 9.4% [1] - Basic earnings per share stood at 1.43 yuan [1] R&D Pipeline - As of July 31, 2025, the company had a total of 39 products in the research and development pipeline [1] - Among these, 13 products are in the registration phase, 4 in Phase III clinical trials, 2 in process validation/bioequivalence stage, and 4 in Phase II clinical trials [1] - The company emphasized the successful implementation of R&D results, supported by optimized management and deep application of AI digital tools [1]

Group 1 - Lijun Group (000513.SZ) reported its 2025 semi-annual results, with 39 institutional investors holding a total of 303 million shares, representing 33.47% of the total share capital [1] - The top ten institutional investors collectively hold 33.12% of the shares, a decrease of 1.85 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, seven funds increased their holdings, including Southern CSI 500 ETF and Huaxia National Vaccine and Biotechnology Index Fund A, while three funds reduced their holdings [2] - A total of 20 new public funds disclosed their holdings this period, with notable mentions including China Europe Medical Health Mixed Fund A and Guotai Health Stock A [2] - One social security fund increased its holdings, while one was no longer disclosed [2] - One insurance fund reduced its holdings, specifically Ruizhong Life Insurance's proprietary funds [2] Group 3 - Foreign investment sentiment showed a decrease in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a reduction of 1.33% [3] - One foreign institution, the Macao Financial Management Bureau, was no longer disclosed this period [3]

Core Viewpoint - The company reported a slight decrease in revenue but a significant increase in profit for the first half of 2025, indicating a stable operational performance despite market challenges [7][8]. Financial Performance - The company achieved a revenue of RMB 6,271.91 million, a decrease of 0.17% compared to RMB 6,282.35 million in the same period last year [7]. - The total profit reached RMB 1,828.11 million, reflecting a year-on-year increase of 13.66% from RMB 1,608.39 million [7]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 1,258.46 million, up 8.91% from RMB 1,155.47 million in the previous year [7]. Business Segments - The company’s various business segments showed mixed results, with growth in digestive, psychiatric, reproductive, and traditional Chinese medicine sectors, while the raw materials and diagnostic segments faced slight declines [8]. - The company’s focus on improving operational efficiency contributed to the increase in total profit and net profit [8]. R&D and Pipeline Development - The company invested approximately RMB 491 million in R&D, accounting for 7.82% of total revenue, supporting its strategic initiatives [8]. - As of July 31, 2025, the company had 39 products in the pipeline, with 13 in the registration phase and 4 in Phase III clinical trials [8][9]. - Key projects include innovative drugs targeting various conditions, with significant progress reported in clinical trials for several products [10][11][12]. Market Expansion and Sales Strategy - The company reported overseas revenue of approximately RMB 1.004 billion, an increase of 18.40%, accounting for 16.01% of total revenue [22]. - The company is actively expanding its presence in international markets, with a focus on local operations and tailored marketing strategies [22][23]. - The company aims to enhance its sales channels and market penetration through a comprehensive approach involving hospitals, grassroots medical institutions, and retail [19][20]. ESG and Sustainability Initiatives - The company has been recognized for its commitment to ESG principles, achieving high ratings in sustainability assessments [29]. - Efforts include enhancing employee welfare, promoting green manufacturing practices, and engaging in community support initiatives [32][31].

Core Insights - Lijun Group is undergoing a transformation from a traditional pharmaceutical company to an innovative international pharmaceutical enterprise, with a focus on steady growth and internationalization [1][2] Financial Performance - In the first half of 2025, the company reported revenue of 6.272 billion yuan, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders reached 1.281 billion yuan, an increase of 9.4% year-on-year [1] - The stable profit growth is attributed to the collaborative efforts across various business segments and structural optimization, with significant contributions from the high-margin specialty raw materials exports [1] R&D Innovation - R&D investment amounted to approximately 491 million yuan, accounting for 7.82% of total revenue, leading to significant advancements in the product pipeline [2] - Multiple key products received approval or are nearing market launch, including injectable aripiprazole microspheres and progesterone injection [2] - Clinical progress has been made in several major disease areas, with notable achievements in the development of IL-17A/F inhibitors and other treatments [2] Globalization Strategy - The company achieved overseas revenue of approximately 1.004 billion yuan, a year-on-year increase of 18.40%, representing 16.01% of total revenue [3] - Growth in overseas revenue is primarily driven by the global competitiveness of the raw materials business, with exports of high-end antibiotics and veterinary drugs showing significant increases [3] - The company is also expanding its international presence through acquisitions and partnerships, including plans to acquire a controlling stake in a Vietnamese company to enhance operational capabilities in Southeast Asia [4]

Core Viewpoint - Lijun Group reported a slight decline in revenue but a significant increase in net profit for the first half of 2025, indicating strong operational efficiency and growth in specific product segments [2][3]. Financial Performance - The company achieved a revenue of 6.272 billion yuan, a year-on-year decrease of 0.17% - Net profit attributable to shareholders was 1.281 billion yuan, a year-on-year increase of 9.4% - Basic earnings per share stood at 1.43 yuan [2]. Product and R&D Development - Major product revenues in the digestive, psychiatric, reproductive, and traditional Chinese medicine sectors all experienced year-on-year growth - R&D investment was approximately 491 million yuan, accounting for 7.82% of total revenue - The company has 39 products in the research pipeline, with 13 in the registration phase and 4 in Phase III clinical trials [2][3]. Business Development and Collaboration - The company introduced 6 projects through business development (BD) in 2024, with 5 successfully entering clinical transformation - The focus for BD in the first half of 2025 included core therapeutic areas such as digestive, psychiatric, metabolic, and anti-infection fields [3]. AI and Patent Strategy - Lijun Group enhanced the application of AI technology throughout the R&D process, including drug design and clinical research - In the first half of 2025, the company submitted 23 patent applications and received 19 domestic patent authorizations, totaling 936 effective patents [3]. International Revenue Growth - The company achieved overseas revenue of approximately 1.004 billion yuan, a year-on-year increase of 18.4% - Overseas revenue accounted for about 16.01% of total revenue, an increase of 2.51 percentage points from the previous year [3].